QT Imaging Holdings Reports 288% Revenue Growth, New FDA Clearance, and Key Distribution Deals in 2025 Annual Report

summarizeSummary

QT Imaging Holdings reported a 288% revenue increase in 2025, secured new FDA clearance and CPT code, and expanded distribution agreements, while also uplisting to Nasdaq and remediating prior material weaknesses, despite continued net losses and potential share dilution.

check_boxKey Events

• Strong Revenue Growth

  Reported a 288% increase in revenue for the year ended December 31, 2025, reaching $18.9 million, up from $4.9 million in 2024, primarily due to the sale of 40 QT Breast Scanners.

• New FDA Clearance and CPT Code Approval

  Received an additional 510(k) FDA clearance on March 10, 2026, for an enhanced Breast Acoustic CT scanner configuration, and the AMA CPT Editorial Panel approved a new Category III CPT code (X579T) for 3D quantitative transmission volumetric ultrasound tomography of the breast, effective January 1, 2027.

• Expanded Distribution Agreements

  Secured minimum order quantities (MOQs) of up to $28.5 million in 2026 from NXC Imaging, $11.2 million to $12.3 million in 2026 from Gulf Medical Co. (Saudi Arabia), and over $24 million for 43 scanners through 2028 from Al Naghi Medical Co. (UAE).

• Uplisting to Nasdaq

  Common stock was uplisted from the OTCQB Venture Market to the Nasdaq Capital Market, effective January 28, 2026, trading under the ticker symbol 'QTI'.

auto_awesomeAnalysis

QT Imaging Holdings' annual report highlights significant operational and commercial progress in 2025 and early 2026. The company achieved a substantial 288% increase in revenue, driven by increased sales of its QT Breast Scanners. Key regulatory milestones were met with a new FDA clearance for enhanced imaging coverage and the approval of a new Category III CPT code, which is crucial for future reimbursement and market adoption. Furthermore, the company expanded its market reach through new distribution agreements with significant minimum order quantities in the US and the Gulf region. The uplisting to Nasdaq Capital Market is a positive development for market visibility and liquidity. While the company reported a notable increase in net loss and faces substantial potential dilution from outstanding warrants, the strong commercial execution and strategic advancements indicate significant momentum for its medical imaging technology.